Sarepta Therapeutics, Inc. (0L35.L)

129,04 +11,63 (+9,91%) Alla chiusura: 07:03PM BST

Sarepta Therapeutics, Inc.

215 First Street
Suite 415
Cambridge, MA 02142
United States
617 274 4000
https://www.sarepta.com

Settore/i: 
Settore: 
Impiegati a tempo pieno: 1.314

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Douglas S. Ingram Esq.	President, CEO & Director	1,66M	N/D	1963
Mr. Ian Michael Estepan	Executive VP & CFO	1,01M	N/D	1976
Dr. Louise R. Rodino-Klapac Ph.D.	Executive VP, Chief Scientific Officer and Head of Research & Development	1,03M	N/D	1978
Mr. Ryan E. Brown J.D.	Executive VP, General Counsel & Corporate Secretary	887,47k	N/D	1978
Mr. Bilal Arif	Executive VP & Chief Technical Operations Officer	829,72k	N/D	1972
Ms. Francesca T. Nolan	Executive Director of Investor Relations and Corporate Communications	N/D	N/D	N/D
Ms. Alison Nasisi	Executive VP & Chief People Officer	N/D	N/D	N/D
Dr. Diane L. Berry Ph.D.	Executive VP and Chief of Global Policy & Advocacy Officer	N/D	N/D	N/D
Mr. Dallan Murray	Executive VP & Chief Customer Officer	N/D	N/D	N/D
Mr. Will Tilton	Senior VP, Head of Strategy & Chief of Staff	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Governance aziendale

L'ISS Governance QualityScore di Sarepta Therapeutics, Inc. al 1 aprile 2024 è 6. I criteri di valutazione fondamentali sono revisione: 7; Consiglio di Amministrazione: 3; diritti degli azionisti: 3; retribuzione: 10.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.